Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MYC | P01106 | 1/20 | 0.44 |
| ▸ | MAX | P61244 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7420683 | 0.86 | KDM4E (0.65) | KDM4EMYCMAXHPGDGAA | |
| SCHEMBL3970182 | 0.83 | KDM4E (0.49) | POLBNPC1KDM4EHPGDGAA | |
| SCHEMBL8673322 | 0.83 | KDM4E (0.54) | KDM4EHPGDGAAALDH1A1MAPT | |
| SCHEMBL6239656 | 0.82 | KDM4E (0.52) | KDM4EHPGDGAAALDH1A1MAPT | |
| SCHEMBL14126567 | 0.82 | KDM4E (0.46) | POLBNPC1KDM4EMYCMAX | |
| SCHEMBL9184895 | 0.81 | KDM4E (0.50) | POLBNPC1KDM4EHPGDGAA | |
| SCHEMBL16431372 | 0.80 | KDM4E (0.54) | KDM4EHPGDGAAALDH1A1MAPT | |
| SCHEMBL16433240 | 0.80 | KDM4E (0.54) | KDM4EHPGDGAAALDH1A1MAPT | |
| SCHEMBL16431209 | 0.80 | KDM4E (0.54) | KDM4EHPGDGAAALDH1A1MAPT | |
| SCHEMBL170164 | 0.80 | KDM4E (0.54) | KDM4EHPGDGAAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5373015-A | Treating hypertension and congestive heart failure | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-12-13 | — | — | US | claimed |
| EP-0539066-A1 | Heterocyclic compounds useful as angiotensin II antagonists | ZENECA LIMITED (GB) | 1993-04-28 | — | — | EP | claimed |
| EP-2168952-B1 | MORPHOLINE DERIVATIVES AS RENIN INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-02-15 | — | — | EP | disclosed |
| EP-1397137-B1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL MYERS SQUIBB CO (US) | 2009-10-14 | — | — | EP | disclosed |
| EP-1758163-B1 | Quinolinols as fluxing and accelerating agents for underfill compositions | HENKEL AG & CO KGAA (DE) | 2009-09-30 | — | — | EP | disclosed |
| US-7482372-B2 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1758163-A1 | Quinolinols as fluxing and accelerating agents for underfill compositions | National Starch and Chemical Investment Holding Corporation (US) | 2007-02-28 | — | — | EP | disclosed |
| US-6962938-B2 | Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| EP-1427408-A4 | CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-$g(a) CONVERTING ENZYME (TACE) | BRISTOL MYERS SQUIBB CO (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20050171096-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | SHEPPECK JAMES E (US) | 2005-08-04 | — | — | US | disclosed |
| US-6906053-B2 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| WO-2002074738-A2 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-26 | — | — | WO | disclosed |
| US-5387592-A | Angiotensin converting enzyme inhibitors, calcium channel blockers, diuretics and adrenergic blocking agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-02-07 | — | — | US | disclosed |
| US-5373015-A | Treating hypertension and congestive heart failure | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-12-13 | — | — | US | disclosed |
| EP-0520723-B1 | Angiotensin II antagonists | ICI PLC (GB) | 1994-06-01 | — | — | EP | disclosed |
| US-5281613-A | Heterocyclic ring substituted benzofuran, benzothiofuran, or indole derivative | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-01-25 | — | — | US | disclosed |
| WO-1993016071-A1 | HETEROCYCLIC DERIVATIVES AS ANGIOTENSIN II ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-19 | — | — | WO | disclosed |
| EP-0539066-A1 | Heterocyclic compounds useful as angiotensin II antagonists | ZENECA LIMITED (GB) | 1993-04-28 | — | — | EP | disclosed |
| EP-0520723-A1 | Angiotensin II antagonists | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-12-30 | — | — | EP | disclosed |
| EP-0520724-A1 | Angiotensin II antagonists | ZENECA LIMITED (GB) | 1992-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171096-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAM17, ADAMTS1, ADAM9 | POLB 2398/4885NPC1 1557/4885KDM4E 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.